Amended Annual Report (10-k/a)
July 13 2020 - 05:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
(Amendment No. 2)
(Mark One)
☒ Annual Report Under Section 13 Or 15(d) Of The Securities
Exchange Act Of 1934
For the fiscal year ended December 31, 2019
or
☐ Transition Report Under Section 13 Or 15(d) Of The Securities
Exchange Act Of 1934
For the transition period from _____ to _____
COMMISSION FILE NUMBER: 001-36374
ACTINIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
74-2963609 |
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
275 Madison Avenue, 7th Fl.
New York, NY 10016
(Address of principal executive offices) (Zip Code)
(646) 677-3870
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each
class |
|
Trading symbol |
|
Name of exchange on which
registered |
| Common stock, par value $0.001 |
|
ATNM |
|
NYSE American |
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act.
Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or 15(d) of the Act.
Yes ☐ No ☒
Indicate by check mark whether the registrant: (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted
electronically every Interactive Date File required to be submitted
pursuant to Rule 405 of Regulation S-T (Section 232.405 of the
chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
smaller reporting company, or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
| Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
| Non-accelerated filer |
☒ |
Smaller reporting
company |
☒ |
| Emerging growth
company |
☐ |
|
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant has filed a report on
and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the
registered public accounting firm that prepared or issued its audit
report. ☐
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the act):
Yes ☐ No ☒
The aggregate market value of voting stock held by nonaffiliates of
the registrant as of June 28, 2019, the last business day of
the registrant’s most recently completed second fiscal quarter,
based on the closing price of the common stock on the NYSE AMERICAN
on June 28, 2019 was $39,794,272.
As of May 7, 2020, 303,343,699 shares of common stock, $0.001 par
value per share, were outstanding.
EXPLANATORY NOTE
Actinium Pharmaceuticals, Inc. (the “Company”) is filing this
Amendment No. 2 on Form 10-K/A (this “Amendment No. 2”) to amend
its Annual Report on Form 10-K for the year ended December 31,
2019, originally filed with the Securities and Exchange Commission
(the “SEC”) on May 8, 2020, as amended by Amendment No. 1 on Form
10-K/A, filed with the SEC on June 16, 2020 (as amended, the
“Original Form 10-K”), solely to disclose that the Company had
filed the Original Form 10-K after the March 30, 2020 deadline
applicable to the Company for the filing of a Form 10-K in reliance
on the 45-day extension provided by an order issued by the U.S.
Securities and Exchange Commission (the “SEC”) under Section 36 of
the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), dated March 4, 2020 (Release No. 34-88318), as modified and
superseded by a new SEC order issued on March 25, 2020 (Release No.
34-88465) (collectively, the “Order”).
On March 27, 2020, the Company filed a Current Report on Form 8-K
to indicate its intention to rely on the Order for such extension.
Consistent with the Company’s statements made in the Form 8-K, the
Company was unable to file the Original Form 10-K until May 8,
2020, and therefore relied on the Order due to circumstances
related to coronavirus, or COVID-19. In particular, COVID-19 had
caused severe disruptions in transportation and limited access to
the Company’s facility, resulting in limited support from its staff
and professional advisors. This, in turn, delayed the Company’s
ability to complete its audit and prepare the Original Form 10-K.
Therefore, due to COVID-19’s interference in the Company’s
operations, the Company was unable to file the Original Form 10-K
prior to the due date.
In accordance with Rules 12b-15 and 13a-14 under the Exchange Act,
the Company has also amended Part IV, Item 15 to include currently
dated certifications pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002 from the Company’s principal executive officer and
principal financial officer. Because no financial statements have
been included in this Amendment No. 2 and this Amendment No. 2 does
not contain or amend any disclosure with respect to Items 307 and
308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications
have been omitted. Similarly, because no financial statements have
been included in this Amendment No. 2, certifications pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 have been
omitted.
Except as described above, this Amendment No. 2 does not amend,
modify or update the information in, or exhibits to, the Original
Form 10-K, and we have not updated disclosures included therein to
reflect any subsequent events. This Amendment No. 2 should be read
in conjunction with the Original Form 10-K and with our other
filings made with the SEC subsequent to the filing of the Original
Form 10-K.
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a) The following documents are filed as part of this report:
(1) Financial Statements.
No financial statements are filed with this Amendment No. 2. These
items were included as part of the Original Form 10-K.
(2) Financial Statement Schedules.
None.
(3) Exhibits
Exhibit
Number |
|
Description |
|
1.1 |
|
Underwriting
Agreement, dated September 28, 2016, by and between H.C. Wainwright
& Co., LLC and Actinium Pharmaceuticals, Inc. (incorporated by
reference to Exhibit 1.1 to Form 8-K filed on September 29,
2016). |
| 1.2 |
|
At Market
Issuance Sales Agreement, dated March 16, 2017, between FBR Capital
Markets & Co, and Actinium Pharmaceuticals, Inc. (incorporated
by reference to Exhibit 1.2 to Form S-3 filed on March 16,
2017). |
| 1.3 |
|
Amended and
Restated At-the-Market Market Issuance Sales Agreement, dated July
3, 2017, among FBR Capital Markets & Co., MLV & Co. LLC,
JonesTrading Institutional Services LLC, and Actinium
Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.5 to
Form 10-Q filed on August 4, 2017). |
| 1.4 |
|
Underwriting
Agreement, dated as of July 28, 2017, by and between Actinium
Pharmaceuticals, Inc. and Oppenheimer & Co. Inc. as
representative of the several underwriters party thereto
(incorporated by reference to Exhibit 1.1 to Form 8-K filed on July
28, 2017). |
| 1.5 |
|
Dealer-Manager
Agreement, dated February 15, 2018, between Maxim Group LLC and
Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 1.1 to Form 8-K filed on February 15,
2018). |
| 1.6 |
|
Underwriting
Agreement, dated April 18, 2019, by and between Actinium
Pharmaceuticals, Inc. and William Blair & Company, LLC
(incorporated by reference to Exhibit 1.1 to Form 8-K filed on
April 18, 2019). |
| 1.7 |
|
Underwriting Agreement, dated as of
April 21, 2020, by and between Actinium Pharmaceuticals, Inc.
and H.C. Wainwright & Co., LLC. (incorporated by reference to
Exhibit 1.1 to Form 8-K filed on April 24, 2020).
|
| 2.1 |
|
Share
Exchange Agreement, dated December 28, 2012, by and among Cactus
Ventures, Inc., Actinium Pharmaceuticals, Inc., Diane S. Button,
and the shareholders of Actinium Pharmaceuticals, Inc.
(incorporated by reference to Exhibit 2.1 to Form 8-K filed on
January 2, 2013). |
| 2.2 |
|
Share
Exchange Agreement, dated March 11, 2013, by and among Cactus
Ventures, Inc., Actinium Pharmaceuticals, Inc, and the shareholders
of Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 10.1 to Form 8-K filed on March 11, 2013). |
| 2.3 |
|
Share
Exchange Agreement, dated August 22, 2013, by and
among Actinium Pharmaceuticals, Inc, Actinium Corporation, and
the shareholders of Actinium Corporation (incorporated by
reference to Exhibit 2.3 to Form S-1/A filed on August 22,
2013). |
| 3.1 |
|
Certificate
of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by
reference to Exhibit 3.1 of the Company’s Form 8-K filed with the
SEC on April 17, 2013). |
|
3.2 |
|
Certificate
of Amendment to Certificate of Incorporation filed January 7, 2014
(incorporated by reference to Exhibit 3.5 to Form S-1 filed on
January 31, 2014). |
| 3.3 |
|
Certificate
of Amendment to Certificate of Incorporation filed February 3,
2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed
on February 7, 2014). |
| 3.4 |
|
Certificate
of Amendment to Certificate of Incorporation (incorporated by
reference to Exhibit 3.1 to Form 8-K filed on March 4,
2015). |
| 3.5 |
|
Amended and
Restated Bylaws, dated August 8, 2018 (incorporated by reference to
Exhibit 3.1 to Form 10-Q filed on August 9, 2018). |
| 3.6 |
|
Certificate
of Amendment to Actinium’s Certificate of Incorporation, as
amended, filed on February 26, 2018 (incorporated by reference to
Exhibit 3.1 to Form 8-K filed on February 26,
2018). |
| 3.7 |
|
Certificate of Amendment
to Actinium’s Certificate of Incorporation, as amended, filed on
March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form
10-K filed on March 15, 2019). |
| 3.8 |
|
Amended and Restated Bylaws, dated
May 7, 2020. .(incorporated by reference to Exhibit 3.1 to Form 8-K
filed on May 5, 2020). |
| 4.1 |
|
Form of
Common Stock Warrant, dated December 27, 2013 and January 10,
2014 (incorporated by reference to Exhibit 4.8 to Form S-1
filed on January 31, 2014). |
| 4.2 |
|
Form of
Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed
on February 6, 2015). |
| 4.3 |
|
Form of
Warrant (incorporated by reference to Exhibit 10.1 to Form 8-K
filed on July 28, 2017). |
| 4.4 |
|
Form of
Warrant Agency Agreement between Action Stock Transfer Corporation
and Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 4.1 to Form 8-K filed on February 15,
2018). |
| 4.5 |
|
Form of
Series A Warrant (incorporated by reference to Exhibit 4.2 to Form
8-K filed on February 15, 2018). |
| 4.6 |
|
Form of
Series B Warrant (incorporated by reference to Exhibit 4.3 to Form
8-K filed on February 15, 2018). |
| 4.7 |
|
Form of
Non-Transferable Subscription Rights Certificate (incorporated by
reference to Exhibit 4.4 to Form 8-K filed on February 15,
2018). |
| 4.8 |
|
Revised Form
of Non-Transferable Subscription Rights Certificate. (incorporated
by reference to Exhibit 4.1 to Form 8-K filed on February 26,
2018). |
| 4.9 |
|
Amendment to
Warrant to Purchase Common Stock, dated November 8, 2018, issued to
Amrosan LLC (incorporated by reference to Exhibit 4.1 to Form 10-Q
filed on November 9, 2018). |
| 4.10 |
|
Amendment to
Warrant to Purchase Common Stock, dated November 8, 2018, issued to
Carnegie Hill Partners (incorporated by reference to Exhibit 4.2 to
Form 10-Q filed on November 9, 2018). |
| 4.11 |
|
Amendment to
Warrant to Purchase Common Stock, dated November 8, 2018, issued to
Bioche Asset Management, LLC (incorporated by reference to Exhibit
4.3 to Form 10-Q filed on November 9, 2018). |
| 4.12 |
|
Form of
Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed
on April 18, 2019). |
| 4.13 |
|
Form of Pre-Funded Warrant
(incorporated by reference to Exhibit 4.1 to Form 8-K filed on
April 24, 2020).
|
| 4.14 |
|
Description of Securities. |
| 10.1 |
|
Third
Amendment to the 2013 Amended and Restated Stock Plan, effective as
of December 22, 2015 (incorporated by reference to Exhibit 10.56 to
Form 10-K filed on March 11, 2016). |
| 10.2 |
|
Office Space
License Agreement, dated March 19, 2016, by and between Actinium
Pharmaceuticals, Inc. and Relmada Therapeutics, Inc. (incorporated
by reference to Exhibit 10.57 to Form 10-K filed on March 11,
2016). |
| 10.3** |
|
Fourth
Amendment to the 2013 Amended and Restated Stock Plan, effective as
of December 13, 2016 (incorporated by reference to Exhibit 1.1 to
Form 8-K filed on December 14, 2016). |
| 10.4** |
|
Fifth
Amendment to the 2013 Amended and Restated Stock Plan, as amended
(incorporated by reference to Exhibit 10.59 to Form 10-K filed on
March 16, 2017). |
| 10.5** |
|
Amendment to
Employment Agreement, dated March 16, 2017, by and between Actinium
Pharmaceuticals, Inc. and Dragan Cicic. (incorporated by reference
to Exhibit 10.60 to Form 10-K filed on March 16,
2017). |
| 10.6 |
|
Amendment to
Actinium Pharmaceuticals, Inc. Warrant to Purchase Common Stock,
dated March 14, 2017 issued to Sandesh Seth (incorporated by
reference to Exhibit 10.61 to Form 10-K filed on March 16,
2017). |
| 10.7 |
|
Amendment to
Actinium Pharmaceuticals, Inc. Warrant to Purchase Common Stock,
dated March 14, 2017 issued to Amrosan LLC (incorporated by
reference to Exhibit 10.62 to Form 10-K filed on March 16,
2017). |
| 10.8 |
|
Warrant to
Purchase Common Stock of Actinium Pharmaceuticals, Inc., dated
March 14, 2017, issued to Sandesh Seth (incorporated by reference
to Exhibit 10.63 to Form 10-K filed on March 16,
2017). |
| 10.9** |
|
Offer
Letter, dated December 27, 2016, by and between Dr. Mark S. Berger
and Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 10.64 to Form 10-K filed on March 16,
2017). |
| 10.10 |
|
Confidential
Information and Invention Assignment Agreement, dated December 27,
2016, by and between Dr. Mark S. Berger and Actinium
Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.65
to Form 10-K filed on March 16, 2017). |
| 10.11** |
|
Indemnification
Agreement, dated March 16, 2017, by and between Actinium
Pharmaceuticals, Inc. and Mark S. Berger (incorporated by reference
to Exhibit 10.66 to Form 10-K filed on March 16,
2017). |
| 10.12** |
|
Director
Agreement, dated March 28, 2017, between Ajit S. Shetty and
Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 10.1 to Form 8-K filed on March 28, 2017). |
| 10.13** |
|
Indemnity
Agreement, dated March 28, 2017, between Ajit S. Shetty and
Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 10.2 to Form 8-K filed on March 28, 2017). |
| 10.14 |
|
Confidential
Information and Invention Assignment Agreement, dated March 28,
2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc.
(incorporated by reference to Exhibit 10.3 to Form 8-K filed on
March 28, 2017). |
| 10.15** |
|
Amendment to
Amended and Restated Consulting Agreement, dated May 5, 2017, by
and between Actinium Pharmaceuticals, Inc. and Sandesh Seth
(incorporated by reference to Exhibit 10.1 to Form 8-K filed on May
11, 2017). |
| 10.16** |
|
Offer
Letter, dated September 17, 2015, between Steve O’Loughlin and
Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 10.1 to Form 10-Q filed on May 15, 2017). |
| 10.17** |
|
Indemnification
Agreement, dated May 15, 2017, between Steve O’Loughlin and
Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 10.2 to Form 10-Q filed on May 15, 2017). |
| 10.18 |
|
Assignment
and Consent Agreement, dated June 6, 2017, between 275 Madison
Avenue RPW 1 LLC and 275 Madison Avenue RPW 2 LLC, Relmada
Therapeutics, Inc., and Actinium Pharmaceuticals, Inc.
(incorporated by reference to Exhibit 10.1 to Form 10-Q filed on
August 4, 2017). |
| 10.19 |
|
Amended and
Restated License Agreement, Dated June 8, 2017, between Relmada
Therapeutics, Inc., and Actinium Pharmaceuticals, Inc.
(incorporated by reference to Exhibit 10.3 to Form 10-Q filed on
August 4, 2017). |
| 10.20** |
|
Offer
Letter, dated May 26, 2017, between Nitya G. Ray and Actinium
Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.4 to
Form 10-Q filed on August 4, 2017). |
| 10.21** |
|
Agreement,
dated June 6, 2017, between Sergio Traversa and Actinium
Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.6 to
Form 10-Q filed on August 4, 2017). |
| 10.22** |
|
Consulting
Agreement, dated May 22, 2017, between Dragan Cicic and Actinium
Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.7 to
Form 10-Q filed on August 4, 2017). |
| 10.23** |
|
Separation
and Settlement Agreement, dated May 12, 2017, between Kaushik Dave
and Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 10.8 to Form 10-Q filed on August 4, 2017). |
| 10.24** |
|
Separation
and Settlement Agreement, dated May 12, 2017, between Dragan Cicic
and Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 10.9 to Form 10-Q filed on August 4, 2017). |
| 10.25** |
|
Sixth
Amendment to the 2013 Amended and Restated Stock Plan, as amended
(incorporated by reference to Exhibit 10.56 to Form 10-K filed on
March 16, 2018). |
| 10.26** |
|
Offer
Letter, effective January 2, 2018, between Dale L. Ludwig and
Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 10.57 to Form 10-K filed on March 16,
2018). |
| 10.27** |
|
Indemnification
Agreement, dated January 5, 2018, between Dale L. Ludwig and
Actinium Pharmaceuticals, Inc. (incorporated by reference to
Exhibit 10.58 to Form 10-K filed on March 16,
2018). |
| 10.28** |
|
Offer
Letter, effective January 31, 2018, between Anil Kapur and Actinium
Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.59
to Form 10-K filed on March 16, 2018). |
| 10.29** |
|
Indemnification
Agreement, dated February 8, 2018, between Anil Kapur and Actinium
Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.60
to Form 10-K filed on March 16, 2018). |
| 10.30** |
|
Director
Agreement, dated April 27, 2018, by and between Actinium
Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by
reference to Exhibit 10.1 to Form 8-K filed on May 1,
2018). |
| 10.31** |
|
Indemnity
Agreement, dated April 27, 2018, by and between Actinium
Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by
reference to Exhibit 10.2 to Form 8-K filed on May 1,
2018). |
| 10.32 |
|
Confidential
Information and Invention Assignment Agreement, dated April 27,
2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W.
Chell (incorporated by reference to Exhibit 10.3 to Form 8-K filed
on May 1, 2018). |
| 10.33** |
|
Employment
Agreement, dated August 8, 2018, by and between Actinium
Pharmaceuticals, Inc. and Sandesh Seth (incorporated by reference
to Exhibit 10.1 to Form 10-Q filed on August 9,
2018). |
| 10.34** |
|
Employment
Agreement, dated August 8, 2018, by and between Actinium
Pharmaceuticals, Inc. and Steve O’Loughlin (incorporated by
reference to Exhibit 10.2 to Form 10-Q filed on August 9,
2018). |
| 10.35 |
|
Purchase
Agreement, dated October 18, 2018, by and between Actinium
Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC
(incorporated by reference to Exhibit 10.1 to Form 8-K filed on
October 18, 2018). |
| 10.36 |
|
Registration
Rights Agreement, dated October 18, 2018, by and between Actinium
Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC
(incorporated by reference to Exhibit 10.2 to Form 8-K filed on
October 18, 2018). |
| 10.37** |
|
Consulting Agreement,
dated December 21, 2018, between Actinium Pharmaceuticals, Inc. and
Nitya Ray (incorporated by reference to Exhibit 10.37 to Form 10-K
filed on March 15, 2019). |
| 10.38 |
|
Amended and Restated At
Market Issuance Sales Agreement, dated December 28, 2018, by and
among Actinium Pharmaceuticals, Inc. and B. Riley FBR, Inc. and
JonesTrading Institutional Services LLC (incorporated by reference
to Exhibit 10.38 to Form 10-K filed on March 15,
2019). |
| 10.39** |
|
Seventh Amendment to the 2013 Amended
and Restated Stock Plan, as amended (incorporated by reference to
Exhibit 10.39 to Form 10-K filed on March 15, 2019).
|
| 14.1 |
|
Code of
Ethics (incorporated by reference to Exhibit 14.1 to Form 8-K filed
on January 2, 2013). |
| 21.1 |
|
List of
Subsidiaries (incorporated by reference to Exhibit 21.1 to Form
10-K filed on March 16, 2015). |
| 23.1 |
|
Consent of Marcum
LLP. |
| 31.1* |
|
Certification of
Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as
adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002. |
| 31.2* |
|
Certification of
Principal Financial and Accounting Officer, pursuant to 18 U.S.C.
Section 1350 as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002. |
| 32.1 |
|
Certification of
Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002. |
| 32.2 |
|
Certification of
Principal Financial and Accounting Officer, pursuant to 18 U.S.C.
Section 1350 as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002. |
| |
|
|
| 101.INS |
|
XBRL Instance
Document |
| 101.SCH |
|
XBRL Taxonomy
Schema |
| 101.CAL |
|
XBRL Taxonomy
Calculation Linkbase |
| 101.DEF |
|
XBRL Taxonomy Definition
Linkbase |
| 101.LA |
|
XBRL Taxonomy Label
Linkbase |
| 101.PRE |
|
XBRL Taxonomy
Presentation Linkbase |
* Filed herewith.
** Indicates a management contract or
compensatory plan or arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons on
behalf of the Registrant.
| Dated: July 13, 2020 |
ACTINIUM
PHARMACEUTICALS, INC. |
| |
|
|
| |
By: |
/s/ Sandesh Seth |
| |
|
Sandesh Seth |
| |
|
Chairman and Chief Executive
Officer (Duly Authorized Officer,
Principal Executive Officer) |
| |
|
|
| |
By: |
/s/ Steve O’Loughlin |
| |
|
Steve O’Loughlin |
| |
|
Principal Financial Officer
(Duly Authorized Officer,
Principal Financial and Accounting Officer)
|
5
